ATE443720T1 - Fc-interferon-beta fusionsproteine - Google Patents
Fc-interferon-beta fusionsproteineInfo
- Publication number
- ATE443720T1 ATE443720T1 AT05766761T AT05766761T ATE443720T1 AT E443720 T1 ATE443720 T1 AT E443720T1 AT 05766761 T AT05766761 T AT 05766761T AT 05766761 T AT05766761 T AT 05766761T AT E443720 T1 ATE443720 T1 AT E443720T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- fusion proteins
- interferon
- ifn
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58338904P | 2004-06-28 | 2004-06-28 | |
PCT/EP2005/006925 WO2006000448A2 (en) | 2004-06-28 | 2005-06-28 | Fc-INTERFERON-BETA FUSION PROTEINS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE443720T1 true ATE443720T1 (de) | 2009-10-15 |
Family
ID=35429166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05766761T ATE443720T1 (de) | 2004-06-28 | 2005-06-28 | Fc-interferon-beta fusionsproteine |
Country Status (9)
Country | Link |
---|---|
US (3) | US7670595B2 (de) |
EP (1) | EP1761559B1 (de) |
JP (1) | JP4808709B2 (de) |
AT (1) | ATE443720T1 (de) |
AU (1) | AU2005256519B2 (de) |
CA (1) | CA2572015C (de) |
DE (1) | DE602005016799D1 (de) |
ES (1) | ES2332924T3 (de) |
WO (1) | WO2006000448A2 (de) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
PT1366067E (pt) | 2001-03-07 | 2012-11-29 | Merck Patent Gmbh | Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
KR100900166B1 (ko) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
HU229098B1 (hu) | 2001-12-04 | 2013-07-29 | Merck Patent Gmbh | Megváltoztatott szelektivitású immuncitokinek |
PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
ES2342964T3 (es) * | 2004-12-09 | 2010-07-20 | Merck Patent Gmbh | Variantes de la interleucina-7 con inmunogenicidad reducida. |
EP1899368A2 (de) * | 2005-05-26 | 2008-03-19 | Schering Corporation | Interferon-igg-fusion |
US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗cd19抗体 |
ES2384055T3 (es) * | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
FR2907454B1 (fr) * | 2006-10-18 | 2009-01-23 | Biomethodes Sa | Variants ameliores de l'interferon beta humain |
EP2572734B1 (de) | 2006-10-31 | 2016-04-06 | East Carolina University | Cytokinbasierte Fusionsproteine zur Behandlung von Immunstörungen |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP2109457B1 (de) | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutische anwendung von kazal-serinproteasehemmern |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
EP3150218B1 (de) * | 2007-09-21 | 2021-09-08 | The Regents Of The University Of California | Gezieltes interferon mit potenten apoptotischen und antitumorwirkungen |
JP5314033B2 (ja) * | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | 突然変異IgGFcフラグメントと融合した単一IFN−ベータ |
US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
EP3348275A3 (de) | 2009-03-31 | 2018-10-24 | East Carolina University | Cytokine und neuroantigene zur behandlung von immunerkrankungen |
CN102405230A (zh) * | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | 具有修饰的FcRn结合位点的抗体融合蛋白 |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP2535057A2 (de) | 2010-02-09 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Zusammensetzung zur behandlung von infektions- und tumorerkrankungen |
EP2371857A1 (de) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Faktor-XII-Inhibitoren zur Behandlung von interstitieller Pneumonie |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
WO2012065059A2 (en) * | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Treatment of atherosclerosis with bmp-alk3 antagonists |
CN102585013B (zh) * | 2011-01-07 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 一种含有ω干扰素的融合蛋白及制备方法 |
US9803210B2 (en) | 2011-02-11 | 2017-10-31 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
EP2497489A1 (de) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Faktor XII-Hemmer zur Behandlung von schleichender Ischämie und Ischämie in anderen Organen |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
CA2832581C (en) | 2011-04-08 | 2022-08-23 | Yumei Xiong | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
US8936782B2 (en) * | 2011-11-22 | 2015-01-20 | Cedars-Sinai Medical Center | Interferon beta as antibacterial agents |
CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
WO2013103981A1 (en) * | 2012-01-06 | 2013-07-11 | Ember Therapeutics, Inc. | Compositions and methods of use of fndc5 polypeptides |
BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
EP2830646B1 (de) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
EP3640375A3 (de) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Verfahren zur rezeptorligandenidentifikation mit hohem durchsatz |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
WO2014124217A1 (en) * | 2013-02-07 | 2014-08-14 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
WO2014128701A1 (en) | 2013-02-20 | 2014-08-28 | Yeda Research And Development Co. Ltd. | Interferon treatment targeting mutant p53 expressing cells |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
US20160024181A1 (en) * | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
UA117008C2 (uk) | 2013-03-14 | 2018-06-11 | Шир Хьюман Дженетік Терапіс, Інк. | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ |
EP3431592A1 (de) * | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Therapeutische mrna-zusammensetzungen und verwendung zur behandlung von krankheiten und störungen |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
PT3027642T (pt) * | 2013-07-31 | 2020-10-30 | Amgen Inc | Construtos do fator 15 de diferenciação de crescimento (gdf-15) |
CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
EP3501605B1 (de) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna-therapie für argininosuccinat-synthase-mangel |
CN103570836B (zh) * | 2013-10-25 | 2016-03-16 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪干扰素β1-Fc融合蛋白及其编码基因和表达方法 |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
LT3105246T (lt) | 2014-02-10 | 2021-08-25 | Merck Patent Gmbh | Tikslinis tgf beta slopinimas |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
CA2944138C (en) * | 2014-03-31 | 2023-06-20 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
PT3480213T (pt) * | 2014-06-18 | 2020-02-04 | Albert Einstein College Of Medicine | Polipéptidos syntac e utilizações dos mesmos |
AU2015283822B2 (en) | 2014-07-02 | 2019-10-03 | CSL Behring Lengnau AG | Modified von willebrand factor |
ES2883158T3 (es) | 2014-07-30 | 2021-12-07 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
WO2016044676A2 (en) * | 2014-09-18 | 2016-03-24 | AskGene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
CA2965414C (en) | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
PE20171058A1 (es) | 2014-10-31 | 2017-07-21 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos |
CN104530213A (zh) * | 2014-11-24 | 2015-04-22 | 广西大学 | 一种病毒性肝炎治疗药物干扰素的生产工艺 |
KR101838919B1 (ko) * | 2015-03-03 | 2018-03-15 | 에이비온 주식회사 | 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법 |
DK3298036T3 (da) | 2015-05-22 | 2022-06-07 | CSL Behring Lengnau AG | Fremgangsmåder til forberedelse af modificeret von Willebrand faktor |
KR20180006453A (ko) | 2015-05-22 | 2018-01-17 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
US11820807B2 (en) | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
JP6953020B2 (ja) * | 2015-09-08 | 2021-10-27 | セリピオン, インコーポレイテッド | ApoA−1融合ポリペプチドならびに関連する組成物および方法 |
WO2017062253A2 (en) * | 2015-10-05 | 2017-04-13 | Circle33 Llc | Antibodies with improved stability to intestinal digestion |
EP3184149A1 (de) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Lösliches glycoprotein v zur behandlung von thrombose-erkrankungen |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
WO2017117630A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated von willebrand factor |
US11510966B2 (en) | 2016-04-15 | 2022-11-29 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 in treating necrotizing enterocolitis |
JP7071288B2 (ja) | 2016-05-18 | 2022-05-18 | キュー バイオファーマ, インコーポレイテッド | T細胞調節多量体ポリペプチド及びその使用方法 |
IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
EP3496737B1 (de) * | 2016-08-15 | 2021-11-03 | The Children's Medical Center Corporation | Apom-fc-fusionsproteine, komplexe davon mit sphingosin-i-phosphat (sip) und verfahren zur behandlung von vaskulären und nicht-vaskulären erkrankungen |
DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
SI3558339T1 (sl) | 2016-12-22 | 2024-05-31 | Cue Biopharma, Inc. | Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
IL309479A (en) | 2017-03-15 | 2024-02-01 | Cue Biopharma Inc | Methods for modulating an immune response |
CN110678550B (zh) | 2017-03-29 | 2023-11-14 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
PE20200150A1 (es) * | 2017-04-21 | 2020-01-17 | Genentech Inc | Uso de antagonistas de klk5 para el tratamiento de una enfermedad |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
BR112019026743A2 (pt) | 2017-06-22 | 2020-06-30 | CSL Behring Lengnau AG | modulação da imunogenicidade de fviii através de vwf truncado |
EP3737689A4 (de) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2020234195A1 (en) | 2019-05-17 | 2020-11-26 | Universitaet Zuerich | Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke |
US20220389082A1 (en) | 2019-07-04 | 2022-12-08 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
WO2021110071A1 (en) | 2019-12-02 | 2021-06-10 | The Hong Kong Polytechnic University | Methods for inducing intermittent fasting and modulating autophagy |
BR112022022035A2 (pt) * | 2020-04-29 | 2023-01-03 | Abion Inc | Interferon-beta humano variante, polinucleotídeo, vetor de expressão, célula animal transformada, métodos para preparar um interferon-beta humano variante, melhorar a estabilidade de um interferon-beta r27t humano variante e tratar uma doença, composição farmacêutica e uso |
EP4144761A4 (de) * | 2020-04-29 | 2024-05-29 | GenoPharm Inc. | Rekombinantes protein mit fusioniertem interferon-beta-mutein und -antikörper sowie pharmazeutische zusammensetzung damit |
WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
EP4211149A1 (de) | 2020-09-09 | 2023-07-19 | Cue Biopharma, Inc. | Mhc klasse ii t-zell-modulierende multimere polypeptide zur behandlung von typ 1 diabetes mellitus (t1d) und verfahren zur verwendung davon |
CA3206884A1 (en) | 2021-02-01 | 2022-08-04 | Kevin AKERET | Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke |
JPWO2022177018A1 (de) * | 2021-02-22 | 2022-08-25 | ||
CA3217518A1 (en) | 2021-05-07 | 2022-11-10 | Rebecca Butcher | Expression system for producing a recombinant haptoglobin (hp) beta chain |
WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
WO2024047219A1 (en) | 2022-09-02 | 2024-03-07 | Csl Behring Ag | Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
EP0237019A3 (de) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
EP0294703B1 (de) | 1987-06-10 | 1995-05-10 | Dana-Farber Cancer Institute, Inc. | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Hiv感染細胞に殺作用する抗体異種結合体 |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6750329B1 (en) | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
ATE123065T1 (de) | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | Proteine und deren herstellung. |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
WO1993005169A1 (en) | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
DK0706799T3 (da) | 1994-09-16 | 2002-02-25 | Merck Patent Gmbh | Immunkonjugater II |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
ES2225874T3 (es) | 1995-03-10 | 2005-03-16 | Genentech, Inc. | Activacion de receptor mediante gas. |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
EP1037927B1 (de) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CN1318092C (zh) | 1998-04-15 | 2007-05-30 | 利思进药品公司 | 含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物 |
CA2328081A1 (en) | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
EP1088888A4 (de) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | Fusionierte proteine |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
ATE462725T1 (de) | 1998-08-25 | 2010-04-15 | Merck Patent Gmbh | Expression und export von angiostatin und endostatin als immunofusins |
US6646113B1 (en) | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
EA005005B1 (ru) * | 1998-10-16 | 2004-10-28 | Байоджен, Инк. | ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
ID30327A (id) | 1999-01-07 | 2001-11-22 | Lexigen Pharm Corp | EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc |
ATE418340T1 (de) | 1999-05-06 | 2009-01-15 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
HUP0201474A3 (en) | 1999-05-19 | 2002-11-28 | Lexigen Pharmaceuticals Corp L | Expression and export of interferon-alpha proteins as fc fusion proteins |
NZ517184A (en) * | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
JP4793971B2 (ja) | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
ES2373966T3 (es) | 2000-02-24 | 2012-02-10 | Philogen S.P.A. | Composiciones y procedimientos para el tratamiento de la angiogénesis en lesiones patológicas. |
MXPA02011016A (es) | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
EP1392826A2 (de) | 2001-01-18 | 2004-03-03 | MERCK PATENT GmbH | Bifunktionelle fusionsproteine mit glukocerebrosidase-aktivität |
MXPA03007316A (es) | 2001-02-19 | 2003-12-04 | Merck Patent Gmbh | Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida. |
KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
PT1366067E (pt) | 2001-03-07 | 2012-11-29 | Merck Patent Gmbh | Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido |
PL362870A1 (en) | 2001-03-15 | 2004-11-02 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE10119338A1 (de) * | 2001-04-20 | 2002-10-24 | Clariant Gmbh | Verwendung von Copolymerisaten auf Basis von Acrylamidoalkylsulfonsäuren als Verdicker in Zubereitungen enthaltend organische Lösemittel |
KR100900166B1 (ko) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
HU229098B1 (hu) | 2001-12-04 | 2013-07-29 | Merck Patent Gmbh | Megváltoztatott szelektivitású immuncitokinek |
BR0307907A2 (pt) * | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
US6938440B2 (en) * | 2002-11-01 | 2005-09-06 | Michele Smith Designs, Inc. | Jewelry distribution and display combination and kit |
BRPI0317376B8 (pt) | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica |
US20050069521A1 (en) | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US7435788B2 (en) * | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
DK1706428T3 (da) | 2004-01-22 | 2009-11-30 | Merck Patent Gmbh | Anti-cancer-antistoffer med reduceret komplementfiksering |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
ES2342964T3 (es) | 2004-12-09 | 2010-07-20 | Merck Patent Gmbh | Variantes de la interleucina-7 con inmunogenicidad reducida. |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
DK1966244T3 (da) | 2005-12-30 | 2012-04-23 | Merck Patent Gmbh | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 |
JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗cd19抗体 |
ES2384055T3 (es) | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
EP1999154B1 (de) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Gentechnisch hergestellte heterodimere proteindomänen |
EP2038417A2 (de) | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen |
-
2005
- 2005-06-27 US US11/167,767 patent/US7670595B2/en not_active Expired - Fee Related
- 2005-06-28 EP EP05766761A patent/EP1761559B1/de not_active Not-in-force
- 2005-06-28 AU AU2005256519A patent/AU2005256519B2/en not_active Ceased
- 2005-06-28 DE DE602005016799T patent/DE602005016799D1/de active Active
- 2005-06-28 WO PCT/EP2005/006925 patent/WO2006000448A2/en active Application Filing
- 2005-06-28 ES ES05766761T patent/ES2332924T3/es active Active
- 2005-06-28 JP JP2007517216A patent/JP4808709B2/ja not_active Expired - Fee Related
- 2005-06-28 AT AT05766761T patent/ATE443720T1/de not_active IP Right Cessation
- 2005-06-28 CA CA2572015A patent/CA2572015C/en not_active Expired - Fee Related
-
2009
- 2009-02-27 US US12/395,165 patent/US8557232B2/en not_active Expired - Fee Related
-
2013
- 2013-08-26 US US14/010,072 patent/US20140005361A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7670595B2 (en) | 2010-03-02 |
WO2006000448A2 (en) | 2006-01-05 |
CA2572015C (en) | 2014-04-22 |
US8557232B2 (en) | 2013-10-15 |
AU2005256519B2 (en) | 2011-10-13 |
ES2332924T3 (es) | 2010-02-15 |
JP2008508862A (ja) | 2008-03-27 |
DE602005016799D1 (de) | 2009-11-05 |
EP1761559B1 (de) | 2009-09-23 |
US20140005361A1 (en) | 2014-01-02 |
US20060228332A1 (en) | 2006-10-12 |
AU2005256519A1 (en) | 2006-01-05 |
JP4808709B2 (ja) | 2011-11-02 |
CA2572015A1 (en) | 2006-01-05 |
WO2006000448A3 (en) | 2006-03-02 |
US20090191154A1 (en) | 2009-07-30 |
EP1761559A2 (de) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE443720T1 (de) | Fc-interferon-beta fusionsproteine | |
WO2007110231A3 (en) | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES | |
CY1120977T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
BRPI0411112A (pt) | proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga | |
ECSP088262A (es) | Proteínas de fusión de albúmina | |
EA200500019A1 (ru) | Ксиланазы, кодирующие их нуклеиновые кислоты и способы их получения и применения | |
DE60311567D1 (de) | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel | |
EA200602137A1 (ru) | Гидрогелевые препараты интерферона | |
ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
WO2005077042A3 (en) | Albumin fusion proteins | |
TW200505480A (en) | High concentration antibody and protein formulations | |
ATE386808T1 (de) | Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel | |
DE602004018788D1 (de) | Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen | |
ATE530659T1 (de) | Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten | |
ATE420099T1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
MXPA05008688A (es) | Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
ES2340842T3 (es) | Anticuerpos anti-apc no neutralizantes. | |
BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
AR053285A1 (es) | Tratamiento de enfemedades usando un sistema mejorado de expresion regulada | |
EA200401586A1 (ru) | Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста | |
CY1106950T1 (el) | Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων | |
EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака | |
AR053284A1 (es) | Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada | |
EP1558735A4 (de) | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |